Design of a single-center, phase II trial to explore the efficacy and safety of ‘R-ISV-RO’ treatment in advanced tumors

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Ashrafizadeh M, Farhood B, Eleojo Musa A, Taeb S, Najafi M. Damage-associated molecular patterns in tumor radiotherapy. Int. Immunopharmacol. 86, 106761 (2020).
  Medline CASGoogle Scholar
• 2. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 3, e28518 (2014).
  MedlineGoogle Scholar
• 3. Golden EB, Marciscano AE, Formenti SC. Radiation and in-situ tumor vaccination approch. Int. J. Radiat. Oncol. Biol. Pays. 108(4), 891–898 (2020).
  MedlineGoogle Scholar
• 4. Blair TC, Bambina S, Kramer GF et al. Fluorescent tracking identifies key migratory dendritic cells in the lymph node after radiotherapy. Life Sci. Alliance 5(9), e202101337 (2022).
  Medline CASGoogle Scholar
• 5. Roberts EW, Broz ML, Binnewies M et al. Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 30(2), 324–336 (2016).
  Medline CASGoogle Scholar
• 6. Dewan MZ, Galloway AE, Kawashima N et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15(17), 5379–5388 (2009).
  Medline CASGoogle Scholar
• 7. Sia J, Hagekyriakou J, Chindris I et al. Regulatory T cells shape the differential impact of radiation dose-fractionation schedules on host innate and adaptive antitumor immune defenses. Int. J. Radiat. Oncol. Biol. Phys. 111(2), 502–514 (2021).
  MedlineGoogle Scholar
• 8. Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18(9), 558–576 (2021).
  Medline CASGoogle Scholar
• 9. Nanda J, Bermudez R. Imiquimod. StatPearls Publishing, FL, USA (2022).
  Google Scholar
• 10. Shi LZ, Bonner JA. Bridging radiotherapy to immunotherapy: the IFN-JAK-STAT axis. Int. J. Mol. Sci. 22(22), 12295 (2021).
  Medline CASGoogle Scholar
• 11. Cho JH, Lee HJ, Ko HJ et al. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma. Oncotarget 8(15), 24932–24948 (2017).
  MedlineGoogle Scholar
• 12. Fu Y, Lin Q, Zhang Z, Zhang L. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm. Sin. B 10(3), 414–433 (2020). • This paper provides molecular proof of the antitumor immunological activity of OX40 agonist.
  Medline CASGoogle Scholar
• 13. Niknam S, Barsoumian HB, Schoenhals JE et al. Radiation followed by OX40 stimulation drives local and abscopal antitumor effects in an anti-PD1-resistant lung tumor model. Clin. Cancer Res. 24(22), 5735–5743 (2018).
  Medline CASGoogle Scholar
• 14. Chu Y, Li R, Qian L et al. Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination. Cancer Sci. 112(11), 4490–4500 (2021). •• This paper provides a preliminary validation of the antitumor activity and safety of injection of the RO compound into the tumor lesions and provides the basis for conducting clinical trials.
  Medline CASGoogle Scholar
• 15. Alsaab HO, Sau S, Alzhrani R et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front. Pharmacol. 8, 561 (2017).
  MedlineGoogle Scholar
• 16. Sato H, Okonogi N, Yoshimoto Y, Tamaki T, Suzuki Y. Radiotherapy and PD-L1 expression. Gan To Kagaku Ryoho 46(5), 845–849 (2019).
  Medline CASGoogle Scholar
• 17. Morisada M, Clavijo PE, Moore E et al. PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. Oncoimmunology 7(3), e1395996 (2017).
  MedlineGoogle Scholar
• 18. Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21(6), 360–378 (2021).
  Medline CASGoogle Scholar
• 19. Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. 21(7), 529–540 (2022). •• This paper presents a definition of adaptive immune resistance, providing a new approach and theoretical basis for combating tumor immune tolerance.
  Medline CASGoogle Scholar
• 20. Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223–249 (2021).
  Medline CASGoogle Scholar
• 21. Zaretsky JM, Garcia-Diaz A, Shin DS et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375(9), 819–829 (2016).
  Medline CASGoogle Scholar
• 22. Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 11(11), 5365–5386 (2021). •• Based on the degree of infiltration of tumor-infiltrating lymphocytes in the tumor microenvironment, the current authors immunologize the tumor immune microenvironment to further analyze the micromechanisms associated with tumor immunotherapy.
  Medline CASGoogle Scholar
• 23. De Guillebon E, Dardenne A, Saldmann A et al. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. Int. J. Cancer 147(6), 1509–1518 (2020).
  MedlineGoogle Scholar
• 24. Wu K, Lin K, Li X et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front. Immunol. 11, 1731 (2020).
  Medline CASGoogle Scholar
• 25. Li C, Jiang P, Wei S, Xu X, Wang J. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol. Cancer 19(1), 116 (2020).
  MedlineGoogle Scholar
• 26. Groth C, Hu X, Weber R et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br. J. Cancer 120(1), 16–25 (2019).
  Medline CASGoogle Scholar
• 27. Pu Y, Ji Q. Tumor-associated macrophages regulate PD-1/PD-L1 immunosuppression. Front. Immunol. 13, 874589 (2022).
  Medline CASGoogle Scholar
• 28. Bonaventura P, Shekarian T, Alcazer V et al. Cold tumors: a therapeutic challenge for immunotherapy. Front. Immunol. 10, 168 (2019).
  Medline CASGoogle Scholar
• 29. Bule P, Aguiar SI, Aires-Da-Silva F, Dias JNR. Chemokine-directed tumor microenvironment modulation in cancer immunotherapy. Int. J. Mol. Sci. 22(18), 9804 (2021).
  Medline CASGoogle Scholar
• 30. Larson C, Oronsky B, Carter CA et al. TGF-beta: a master immune regulator. Expert Opin.Ther. Targets 24(5), 427–438 (2020).
  Medline CASGoogle Scholar
• 31. Lim KH, Staudt LM. Toll-like receptor signaling. Cold Spring Harb. Perspect. Biol. 5(1), a011247 (2013). • This paper provides molecular proof of the antitumor immunological activity of R837 (Toll-like receptor agonist).
  MedlineGoogle Scholar
• 32. Luchner M, Reinke S, Milicic A. TLR agonists as vaccine adjuvants targeting cancer and infectious diseases. Pharmaceutics 13(2), 142 (2021).
  Medline CASGoogle Scholar
• 33. Huang SW, Liu KT, Chang CC et al. Imiquimod simultaneously induces autophagy and apoptosis in human basal cell carcinoma cells. Br. J. Dermatol. 163(2), 310–320 (2010).
  Medline CASGoogle Scholar
• 34. Jiang J, Dong L, Shi HT et al. Imiquimod inhibits the growth of SGC-7901 cells in vitro through induction of autophagy and apoptosis. Mol. Med. Rep. 13(1), 393–397 (2016).
  Medline CASGoogle Scholar
• 35. Meng Z, Fang X, Fu B et al. Tumor immunotherapy boosted by R837 nanocrystals through combining chemotherapy and mild hyperthermia. J. Control. Release 350, 841–856 (2022).
  Medline CASGoogle Scholar
• 36. Kim TW, Burris HA, de Miguel Luken MJ et al. First-in-human phase I study of the OX40 agonist MOXR0916 in patients with advanced solid tumors. Clin. Cancer Res. 28(16), 3452–3463 (2022).
  Medline CASGoogle Scholar
• 37. Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat. Rev. Clin. Oncol. 19(1), 37–50 (2022).
  Medline CASGoogle Scholar
• 38. Ma Y, Li J, Wang H et al. Combination of PD-1 inhibitor and OX40 agonist induces tumor rejection and immune memory in mouse models of pancreatic cancer. Gastroenterology 159(1), 306–319.e12 (2020).
  Medline CASGoogle Scholar
• 39. Yadav R, Redmond WL. Current clinical trial landscape of OX40 agonists. Curr. Oncol. Rep. 24(7), 951–960 (2022).
  Medline CASGoogle Scholar
• 40. Davis EJ, Martin-Liberal J, Kristeleit R et al. First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors. J. Immunother. Cancer 10(10), e004235 (2022).
  MedlineGoogle Scholar
• 41. Gutierrez M, Moreno V, Heinhuis KM et al. OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors. Clin. Cancer Res. 27(2), 460–472 (2021).
  Medline CASGoogle Scholar
• 42. Sagiv-Barfi I, Czerwinski DK, Levy S et al. Eradication of spontaneous malignancy by local immunotherapy. Sc. Transl. Med. 10(426), eaan4488 (2018).
  MedlineGoogle Scholar
• 43. Zhou Z, Lin L, An Y et al. The combination immunotherapy of TLR9 agonist and OX40 agonist via intratumoural injection for hepatocellular carcinoma. J. Hepatocell. Carcinoma 8, 529–543 (2021).
  MedlineGoogle Scholar
• 44. Chen Q, Chen J, Yang Z et al. Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy. Adv. Mater. 31(10), e1802228 (2019).
  MedlineGoogle Scholar
• 45. Jiang X, Wang J, Zheng X et al. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy. J. Immunother. Cancer 10(5), e003960 (2022).
  MedlineGoogle Scholar
• 46. Champiat S, Tselikas L, Farhane S et al. Intratumoral immunotherapy: from trial design to clinical practice. Clin. Cancer Res. 27(3), 665–679 (2021).
  Medline CASGoogle Scholar
• 47. Igarashi Y, Sasada T. Cancer vaccines: toward the next breakthrough in cancer immunotherapy. J. Immunol. Res. 2020, 5825401 (2020).
  MedlineGoogle Scholar
• 48. Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol. Oncol. 14(12), 2994–3006 (2020). • This paper explains the immunological mechanisms of radiation therapy in playing the effect of the in situ vaccine.
  Medline CASGoogle Scholar
• 49. Sato H, Okonogi N, Nakano T. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment. Int. J. Clin. Oncol. 25(5), 801–809 (2020).
  Medline CASGoogle Scholar
• 50. Zhao X, Shao C. Radiotherapy-mediated immunomodulation and anti-tumor abscopal effect combining immune checkpoint blockade. Cancers (Basel) 12(10), 2762 (2020).
  Medline CASGoogle Scholar
• 51. Zhang W, Yan C, Gao X et al. Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma. Oncologist 26(7), e1110–e1124 (2021).
  Medline CASGoogle Scholar
• 52. Maity A, Mick R, Huang AC et al. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Br. J. Cancer 119(10), 1200–1207 (2018).
  Medline CASGoogle Scholar
• 53. Marabelle A, Tselikas L, de Baere T, Houot R. Intratumoral immunotherapy: using the tumor as the remedy. Ann. Oncol. 28(Suppl. 12), S33–S43 (2017).
  Google Scholar
• 54. Monga V, Miller BJ, Tanas M et al. Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial. J. Immunother. Cancer 9(7), e003119 (2021).
  MedlineGoogle Scholar
• 55. Seo YD, Lu H, Black G et al. Toll-like receptor 4 agonist injection with concurrent radiotherapy in patients with metastatic soft tissue sarcoma: a phase 1 nonrandomized controlled trial. JAMA Oncol. 9(12), 1660–1668 (2023).
  MedlineGoogle Scholar
• 56. Ji S, Huang L, Chang S et al. Albumin pre-opsonized membrane-active iPep nanomedicine potentiates chemo to immunotherapy of cancer. Biomaterials 301, 122269 (2023).
  Medline CASGoogle Scholar